Results 1 to 10 of about 3,798 (162)

Terlipressin-induced hyponatremic encephalopathy in a noncirrhotic patient [PDF]

Kaohsiung Journal of Medical Sciences, 2013
Terlipressin, an analogue of vasopressin, is frequently used for the management of esophageal varices bleeding and hepatorenal syndrome. Terlipressin therapy in portal hypertensive patients is frequently associated with hyponatremia, but is rarely ...
Yao-Kuang Wang, Daw-Yang Hwang, Sophie S.W. Wang, Shang-Jyh Hwang, Li-Tzong Chen, Mei-Chuan Kuo   +5 more
doaj   +3 more sources

Pharmacokinetic and pharmacodynamic analyses of terlipressin in patients with hepatorenal syndrome

AAPS Open, 2022
The objective of this population pharmacokinetics (PK) analysis was to characterize the PK of terlipressin and its active metabolite, lysine-vasopressin (L-VP), in patients with hepatorenal syndrome (HRS), following intravenous administration of ...
Khurram Jamil
exaly   +2 more sources

Vasopressin and Terlipressin in the Treatment of Vasodilatory Septic Shock: A Systematic Review

Proceedings of Singapore Healthcare, 2011
Background: Vasodilatory septic shock unresponsive to fluid resuscitation requires the addition of vasopressors. Catecholamines remain the first line vasopressor therapy, but treatment failure is a potential problem.
Jie Lin Soong BSc (Pharm) (Hons), Wai Hing Lim B Pharm (Hons), M Clin Pharm   +1 more
doaj   +2 more sources

Addition of terlipressin to norepinephrine in septic shock and effect of renal perfusion: a pilot study

Renal Failure, 2022
Purpose Terlipressin improves renal function in patients with septic shock. However, the mechanism remains unclear. Here, we aimed to evaluate the effects of terlipressin on renal perfusion in patients with septic shock.Materials and Methods This pilot ...
Jinlong Wang, Mengjuan Shi, Lili Huang, Qing Li, Shanshan Meng, Jingyuan Xu, Ming Xue, Jianfeng Xie, Songqiao Liu, Yingzi Huang   +9 more
doaj   +2 more sources

Terlipressin in combination with albumin as a therapy for hepatorenal syndrome in patients aged 65 years or older

Annals of Hepatology, 2023
Introduction and Objectives: Clinical data for older patients with advanced liver disease are limited. This post hoc analysis evaluated the efficacy and safety of terlipressin in patients aged ≥65 years with hepatorenal syndrome using data from 3 Phase ...
Muhammad A. Mujtaba, Ann Kathleen Gamilla-Crudo, Shehzad N. Merwat, Syed A. Hussain, Michael Kueht, Aftab Karim, Muhammad W. Khattak, Peggy J. Rooney, Khurram Jamil   +8 more
doaj   +1 more source

Role of Terlipressin in Cirrhotic Patients with Ascites and without Hepatorenal Syndrome: A Systematic Review of Current Evidence

Canadian Journal of Gastroenterology and Hepatology, 2020
Ascites, a common complication in cirrhosis, is prone to the development of acute kidney injury or hepatorenal syndrome and can be complicated by circulatory dysfunction after paracentesis.
Zhaohui Bai, Yang An, Xiaozhong Guo, Rolf Teschke, Nahum Méndez-Sánchez, Hongyu Li, Xingshun Qi   +6 more
doaj   +1 more source

Improvement of gut-vascular barrier by terlipressin reduces bacterial translocation and remote organ injuries in gut-derived sepsis

Frontiers in Pharmacology, 2022
Gut-vascular barrier (GVB) serves as the last barrier to limit the migration of intestinal toxins into the blood circulation. The efficacy of terlipressin (a vasopressin V1 receptor agonist) in reducing GVB and multiple organ damage in gut-derived sepsis
Zenan Chang, Zenan Chang, Yinan Zhang, Ming Lin, Shihong Wen, Hanjin Lai, Yaqing Zhan, Xiufen Zhu, Zhikun Huang, Xuyu Zhang, Zimeng Liu   +10 more
doaj   +1 more source

Terlipressin infusion for prevention of vasoplegic syndrome in patients treated with angiotensin II receptor antagonist undergoing coronary artery bypass graft surgery: a randomized controlled study

Ain Shams Journal of Anesthesiology, 2020
Background and objectives Preoperative use of renin angiotensin system antagonists has been considered an independent risk factor for development of vasoplegic syndrome.
Mohamed Saleh, Sherine Kamal Zaki Kodeira, Abdelkhalek Abdelmoneim Aboulseoud   +2 more
doaj   +1 more source

Safety and efficacy of terlipressin in acute-on-chronic liver failure with hepatorenal syndrome-acute kidney injury (HRS-AKI): a prospective cohort study

Scientific Reports, 2022
Terlipressin with albumin, the recommended treatment for hepatorenal syndrome-acute kidney injury (HRS-AKI), is associated with adverse events. Furthermore, the course of AKI in patients with acute-on-chronic liver failure (ACLF) is unknown.
Anand V. Kulkarni, Sowmya Tirumalige Ravikumar, Harshvardhan Tevethia, Madhumita Premkumar, Karan Kumar, Mithun Sharma, Rajesh Gupta, Padaki Nagaraja Rao, Duvvuru Nageshwar Reddy   +8 more
doaj   +1 more source

Role of Terlipressin in Patients With Hepatorenal Syndrome-Acute Kidney Injury Admitted to the ICU: A Substudy of the CONFIRM Trial

Critical Care Explorations, 2023
IMPORTANCE AND OBJECTIVES:. This study assessed the potential advantages of treating hepatorenal syndrome-acute kidney injury (HRS-AKI) with terlipressin versus placebo in the ICU setting. DESIGN:.
Constantine J. Karvellas, MD, Ram Subramanian, MD, Jody C. Olson, MD, Khurram Jamil, MD   +3 more
doaj   +1 more source